Literature DB >> 10070889

Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.

P Pujol1, J P Daurès, J P Brouillet, T Maudelonde, H Rochefort, J Grenier.   

Abstract

Many studies have addressed the clinical value of pS2 as a marker of hormone responsiveness and of cathepsin D (Cath D) as a prognostic factor in breast cancer. Because pS2 and Cath D are both oestrogen induced in human breast cancer cell lines, we studied the influence of the menstrual cycle phase and menopausal status at the time of surgery on the levels of these proteins in breast cancer. A population of 1750 patients with breast cancer, including 339 women in menstrual cycle, was analysed. Tumoral Cath D and pS2 were measured by radioimmunoassay. Serum oestradiol (E2), progesterone (Pg), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels at the day of surgery were used to define the hormonal phase in premenopausal women. There was a trend towards a higher mean pS2 level in the follicular phase compared with the luteal phase (17 ng mg(-1) and 11 ng mg(-1) respectively, P = 0.09). Mean pS2 was lower in menopausal patients than in women with cycle (8 ng mg(-1) and 14 ng mg(-1) respectively, P = 0.0001). No differences in mean Cath D level were observed between the different phases of the menstrual cycle, or between pre- and post-menopausal women. In the overall population, pS2 was slightly positively associated with E2 and Pg levels and negatively associated with FSH and LH, probably reflecting the link between pS2 and menopausal status. In premenopausal women, no association was found between pS2 and E2, Pg, FSH or LH levels. There were no correlations between Cath D level and circulating hormone levels in the overall population. However, in the subgroup of premenopausal women with ER-positive (ER+) tumours, E2 was slightly associated with both pS2 and Cath D, consistent with oestrogen induction of these proteins in ER+ breast cancer cell lines. There are changes in pS2 level in breast cancer throughout the menstrual cycle and menopause. This suggests that the choice of the pS2 cut-off level should take the hormonal status at the time of surgery into account. In contrast, the level of Cath D is unrelated to the menstrual cycle and menopausal status.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070889      PMCID: PMC2362656          DOI: 10.1038/sj.bjc.6690145

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Cyclical tumour variations in premenopausal women with early breast cancer.

Authors:  R A Badwe; R Bettelheim; R R Millis; W Gregory; M A Richards; I S Fentiman
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Expression of pS2, c-erbB-2, and cathepsin D during the menstrual cycle in human breast cancers.

Authors:  S A Khan; N J Gonchoroff; L E Miller
Journal:  Ann Surg Oncol       Date:  1997-09       Impact factor: 5.344

4.  Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.

Authors:  J J Pink; V C Jordan
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

5.  Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer.

Authors:  M Gion; R Mione; R Dittadi; M Romanelli; L Pappagallo; G Capitanio; U Friede; R Barbazza; A Visonà; S Dante
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

6.  Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors.

Authors:  D J Oliver; D M Ingram
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

7.  Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis.

Authors:  G Ferrandina; G Scambia; F Bardelli; P Benedetti Panici; S Mancuso; A Messori
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Serum progesterone and prognosis in operable breast cancer.

Authors:  P E Mohr; D Y Wang; W M Gregory; M A Richards; I S Fentiman
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

9.  Characteristics of the menstrual cycle at the time of surgery for breast cancer.

Authors:  I M Holdaway; B H Mason; A E Lethaby; J E Harman; J T France; B S Knox
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy.

Authors:  K Holli; J Isola; M Hakama
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more
  1 in total

1.  Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.

Authors:  Milan Markićević; Radan Džodić; Marko Buta; Ksenija Kanjer; Vesna Mandušić; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Int J Med Sci       Date:  2014-05-01       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.